Trial site
Regional Medical Oncology Center
Wilson, North Carolina 27893, United StatesNot linked to an institution yet
- 8running trials
- 1closed trial
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 34 trials
- Phase 23 trials
- Phase 1/21 trial
- Status
- Active, not recruiting6 trials
- Recruiting2 trials
- Withdrawn1 trial
- Lead sponsor
- Janssen Research & Development, LLC2 trials
- Boehringer Ingelheim1 trial
- DualityBio Inc.1 trial
- Epizyme, Inc.1 trial
- Kartos Therapeutics, Inc.1 trial
- and 3 more
Running trials
Recruiting
Pan-tumor MRD Study
NCT06605404· Paradigm Health· Source
Contact: Meredith Best
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135· Phase 3· Kartos Therapeutics, Inc.· Source
Contact: John Mei
Active, not recruiting
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
NCT05482971· Phase 2· PharmaEssentia· Source
Active, not recruiting
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493· Phase 3· Epizyme, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error